Persistent allergic rhinitis (PER) is a frequent disease often associated with co-morbidities (asthma, sinusitis, otitis media and upper respiratory infection) and a significant economic burden. Levocetirizine is an antihistamine, the first-line treatment of allergic rhinitis. OBJECTIVES: To determine the monetary impact of a long-term levocetirizine treatment either from a societal perspective or from an employer perspective. METHODS: XPERT trial was a 6-month double-blind placebo-controlled trial comparing levocetirizine 5 mg once daily to placebo. A total of 551 patients were included (69% working). Parameters measured, all related to PER or its co-morbidities, were health care resources (medications, physician visits and hospitalizations) collected in the case report form as well as workdays and usual daily activities (UDA) lost collected through a specific questionnaire. French monetary values from 2000 were applied and compared using a bootstrap-t analysis. The societal perspective included all costs for all patients while the employer perspective included the cost of workdays lost for working patients. RESULTS: The overall cost from the societal perspective was of 412.93€ per patient per month in the placebo vs. 232.23€ in the levocetirizine group. This led to a gain of 180.70€ per patient per month in the levocetirizine group (p-value <0.001). UDA lost was the cost driver (≥ 66%). The overall costs from an employer perspective was of 152.24€ per working patient per month in the placebo vs. 89.61€ in the levocetirizine group leading to a gain of 62.63€ per working patient per month (p-value <0.001). CONCLUSION: Levocetirizine reduces the overall cost associated with PER and its co-morbidities both for employers and society. These savings are due to a reduction in the cost of work and UDA days lost that more than offset the cost of the levocetirizine treatment.